PAREXEL INTERNATIONAL TO EXHIBIT AT THE 2007 BIO INTERNATIONAL CONVENTION
BOSTON, MA, May 3, 2007 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services provider, will be exhibiting its range of developmental and commercialization services in the largest state pavilion at the 2007 BIO International Convention. Additionally, the Company will be sponsoring a Business Forum Company Presentation Room which gives new biotech companies a chance to present their capabilities to interested groups. The event will be held at the MBC Massachusetts Pavilion on May 6-9, 2007 in Boston, MA. PAREXEL is a Massachusetts Biotech Council (MBC) member and Massachusetts-based, international company.
For the past 25 years, clients have relied on PAREXEL to provide integrated clinical development, regulatory affairs consulting and commercialization services, as well as to offer technologies that expedite time-to-market of potentially life-saving drug compounds. More than 20,000 attendees at the 2007 BIO International Convention, held this year at the Boston Convention & Exhibition Center, can visit PAREXEL’s Booth #533 to learn about the Company’s continuing focus on small/emerging biopharmaceutical companies.
The 2007 BIO International Convention is an annual biotechnology event that seeks to foster awareness and development of the biotechnology industry. Attendees have the opportunity to cultivate business relationships and partnerships while educating policy makers and the general public about the successes and future value of a growing industry.
For more information about PAREXEL, visit www.PAREXEL.com or Booth #533 in the MBC Massachusetts Pavilion at the 2007 BIO International Convention.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 55 locations throughout 43 countries around the world, and has over 6,315 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand, such as the guidance provided by the Company with respect to the fourth quarter of Fiscal Year 2007, Fiscal Year 2007 and Calendar Year 2007. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes”, “anticipates”, “plans”, “expects”, “intends”, “appears”, “estimates”, “projects”, “targets” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2006 as filed with the SEC on February 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.